Table 2.

Outcomes of the included studies

Study, year [ref.]	Overall survival	Efficacy (based on CT)	Adverse effect (bleeding/pneumothorax/radiation lung injury)
Jiakai Li, 2013 [11]	1-y: 95.8% 2-y: 78% 3-y: 55% Median survival time: 38 months (8-46)	At the end of follow-up period: CR: 8 PR: 10 SD: 4 PD: 6	4/3/0
Bin Huo, 2017 [12]	1-y: 100% 2-y: 91.7% 3-y: 72.9%	y LC: 100% y LC: 95.2% y LC: 95.2%	8/10/2
Jingkui Yang, 2014 [13]	1-y: 95.8% 2-y: 81.3% 5-y: 56.3%	1-y LC: 85% (based on PET-CT)	8/12/0
Mingyao Ke, 2011 [14]	1-y: 60% 2-y: 54% 3-y: 50% 4-y: 33%	1-y LC: 69% 2-y LC: 58% 3-y LC: 36% 4-y LC: 11%	1/4/1
Jingkui Yang, 2014 [20]	1-y: 94.4% 2-y: 72.7% 3-y: 66.7% 5-y: 55.6%	6 months after implantation: CR: 7, PR: 9, SD: 2, PD: 0	3/6/0
Hua Cheng, 2019 [21]	1-y: 96.1% 2-y: 80.7% 3-y: 69.2%	6 months after implantation: CR: 10, PR: 12, SD: 4, PD: 0 1-y LC: 84.6%	4/3/0
Wei Fu, 2019 [22]	T: 1-y: 100% 2-y: 92% C: 1-y: 91.67% 2-y: 66.67%	T: short-term efficacy: CR: 4, PR: 12, SD: 9, PD: 0 y LC: 100%, 2-y LC: 92% C: short-term efficacy: CR: 2, PR: 12, SD: 10, PD: 0 y LC: 95.83%, 2-y LC: 62.50%	1/2/0
Jianguo Yang, 2018 [23]	N.A.	T: short-term efficacy: CR: 10, PR: 17, SD: 2, PD: 5 C: short-term efficacy: CR: 8, PR: 10, SD: 2, PD: 13	1/2/0
Xianghua Lin, 2016 [24]	N.A.	T: 6 months after implantation: CR: 4, PR: 14, SD: 2, PD: 0 C: 6 months after implantation: CR: 1, PR: 10, SD: 4, PD: 4	4/3/0

T – treatment group, C – control group, CR – complete response, PR – partial response, SD – stable disease, PD – progressive disease, LC – local control, y – year, N.A. – not available